REVIEWING THE CURRENT LANDSCAPE OF PROBIOTICS IN TREATING INFECTIOUS DISEASES
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
This review provides an overview of the potential of probiotics as a clinical intervention for infectious diseases by examining research and development efforts over the past two decades, as reflected in patents and clinical trials. Data were collected from patent and clinical trial databases to assess the long- and short-term trends in probiotics research. Analysis included the total number of patents and trials for each indication, application dates and locations, and types of applicants/sponsors. A total of 22 infectious diseases were investigated, resulting in 82 patents and 65 clinical trials targeting 18 indications. A consistent increase was observed in the number of patents and clinical trials since 1999, with the highest number focusing on digestive tract, respiratory, and urogenital indications. The findings indicate significant interest in probiotics for infectious diseases, aligning with reported unmet needs and global probiotics sales estimates. However, a decreasing rate of translation from patents to clinical trials suggests potential barriers in the research process.
Article Details
Как цитировать:
Библиографические ссылки:
Binda S., Hill C., Johansen E., Obis D., Pot B., Sanders M. E., et al.. (2020). Criteria to qualify microorganisms as “probiotic” in foods and dietary supplements. Front. Microbiol. 11:1662. doi: 10.3389/fmicb.2020.01662, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Cazorla S. I., Maldonado-Galdeano C., Weill R., De Paula J., Perdigón G. D. (2018). Oral administration of probiotics increases Paneth cells and intestinal antimicrobial activity. Front. Microbiol. 9:736. doi: 10.3389/fmicb.2018.00736, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Couzin-Frankel J. (2021). Antiviral pills could change pandemic’s course. Science 374, 799–800. doi: 10.1126/science.acx9605, PMID: [PubMed] [CrossRef] [Google Scholar]
Cutler D. M., Summers L. H. (2020). The COVID-19 pandemic and the $16 trillion virus. JAMA 324, 1495–1496. doi: 10.1001/jama.2020.19759, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
de Oliveira G. L. V., Oliveira C. N. S., Pinzan C. F., de Salis L. V. V., Cardoso C. R. D. B. (2021). Microbiota modulation of the gut-lung axis in COVID-19. Front. Immunol. 12:635471. doi: 10.3389/fimmu.2021.635471, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Dumas A., Bernard L., Poquet Y., Lugo-Villarino G., Neyrolles O. (2018). The role of the lung microbiota and the gut–lung axis in respiratory infectious diseases. Cell. Microbiol. 20:e12966. doi: 10.1111/cmi.12966, PMID: [PubMed] [CrossRef] [Google Scholar]
Ernst H. (1997). The use of patent data for technological forecasting: the diffusion of CNC-technology in the machine tool industry. Small Bus. Econ. 9, 361–381. doi: 10.1023/A:1007921808138 [CrossRef] [Google Scholar]
Espacenet (2019). Classification Search. Available at: https://worldwide.espacenet.com/classification?locale=en_EP (Accessed November 17, 2021).
European Patent Office (2021). The Patenting Process. Available at: https://www.epo.org/learning/materials/inventors-handbook/protection/patents.html (Accessed November 17, 2021).
Feddema J. J., Claassen E. (2018). Addressing the unmet need in respiratory viruses: an interdisciplinary analysis of product development pipeline in Asia. Int. J. Clin. Trials 5, 1–10. doi: 10.18203/2349-3259.ijct20180001 [CrossRef] [Google Scholar]
Feddema J. J., van der Geest A. M., Claassen E., van de Burgwal L. H. (2021). Lower respiratory tract infection trends in east and South-East Asia: In the light of economic and health care development. Glob. Pediatr. Health 8, 1–9. doi: 10.1177/2333794X21989530, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Fernald K. D. S., Weenen T. C., Sibley K. J., Claassen E. (2013). Limits of biotechnological innovation. Techn. Investment. 4, 168–178. doi: 10.4236/ti.2013.43020 [CrossRef] [Google Scholar]
Flach J., van der Waal M. B., van den Nieuwboer M., Claassen E., Larsen O. F. (2018). The underexposed role of food matrices in probiotic products: reviewing the relationship between carrier matrices and product parameters. Crit. Rev. Food Sci. Nutr. 58, 2570–2584. doi: 10.1080/10408398.2017.1334624, PMID: [PubMed] [CrossRef] [Google Scholar]
Global Health Observatory (2021). Global Health Estimates: Life Expectancy and Leading Causes of Death and Disability. Available at: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates (Accessed December 28, 2021).
Hersh A. L., Newland J. G., Beekmann S. E., Polgreen P. M., Gilbert D. N. (2012). Unmet medical need in infectious diseases. Clin. Infect. Dis. 54, 1677–1678. doi: 10.1093/cid/cis275, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Hill C., Guarner F., Reid G., Gibson G. R., Merenstein D. J., Pot B., et al.. (2014). The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol. 11, 506–514. doi: 10.1038/nrgastro.2014.66, PMID: [PubMed] [CrossRef] [Google Scholar]
Horwitz D., McCue T., Mapes A. C., Ajami N. J., Petrosino J. F., Ramig R. F., et al.. (2015). Decreased microbiota diversity associated with urinary tract infection in a trial of bacterial interference. J. Infect. 71, 358–367. doi: 10.1016/j.jinf.2015.05.014, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Infusino F., Marazzato M., Mancone M., Fedele F., Mastroianni C. M., Severino P., et al.. (2020). Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: a scoping review. Nutrients 12:1718. doi: 10.3390/nu12061718, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
International Probiotics Association (2015). Probiotics: A Need in Developing Countries. Available at: https://internationalprobiotics.org/probiotics-need-developing-countries/ (Accessed January 18, 2022).
International Probiotics Association (2019). European Probiotic Market Insights: 2019. Available at: https://www.ipaeurope.org/legal-framework/market-data/ (Accessed January 18, 2022).
Janse M., Brouwers T., Claassen E., Hermans P., Van de Burgwal L. (2021). Barriers influencing vaccine development timelines, identification, causal analysis, and prioritization of key barriers by KOLs in general and Covid-19 vaccine R&D. Front. Public Health 9:612541. doi: 10.3389/fpubh.2021.612541, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
Janse M. J., Trocha M., Feddema J., Claassen E., Van de Burgwal L. (2020). Identifying the gaps in human and veterinary chlamydia vaccine development. Int. J. Clin. Trials 7, 160–169. doi: 10.18203/2349-3259.ijct20203102 [CrossRef] [Google Scholar]
Jürgens B., Herrero-Solana V. (2015). Espacenet, Patentscope and Depatisnet: a comparison approach. World Patent Inf. 42, 4–12. doi: 10.1016/j.wpi.2015.05.004 [CrossRef] [Google Scholar]
Kane A., Kounang N. (2022). Pfizer’s Covid-19 Antiviral Pill Was Hailed as a Game-Changer, but Supplies Are Scarce. Available at: https://edition.cnn.com/2022/01/12/health/paxlovid-pfizer-antiviral-scarce/index.html (Accessed January 17, 2022).
Kurian S. J., Unnikrishnan M. K., Miraj S. S., Bagchi D., Banerjee M., Reddy B. S., et al.. (2021). Probiotics in prevention and treatment of COVID-19: current perspective and future prospects. Arch. Med. Res. 52, 582–594. doi: 10.1016/j.arcmed.2021.03.002, PMID: